Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
Hypercalcaemia regularly occurs when "prophylactic" 1,25-dihydroxyvitamin D3 (1,25[OH)2D3) in a dose of 1.0 microgram daily is given to haemodialysis patients without clinical biochemical or radiological evidence of osteodystophy. This dose is too large for such patients. Hypercalcaemia may persist for several weeks after withdrawal of 1,25(OH)2D3, particularly when previous attempts at control by dosage reduction have failed. Hypercalcaemia is better managed by stopping 1,25(OH)2D3, albeit temporarily, than by reducing the dose.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000517:prevention & control*; D004100:Dihydroxycholecalciferols / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006934:Hypercalcemia / Q000139:chemically induced; D008875:Middle Aged; D009392:Nephrectomy; D010710:Phosphates / Q000097:blood; D007690:Polycystic Kidney Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006435:Renal Dialysis
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D010710:Phosphates; D000469:Alkaline Phosphatase; D002118:Calcium